MAP Pharmaceuticals, Inc. Announces Expansion At Corporate Headquarters

MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a leading developer of novel inhaled drug therapies, today announced the expansion of its facility at 2400 Bayshore Parkway in Mountain View, California to accommodate the company's recent and anticipated future growth.

MAP Pharmaceuticals has increased its space by 50%, occupying approximately 32,000 square feet at its Mountain View facility. The expansion enables the company to increase its clinical and development capabilities to support its two ongoing Phase 2 clinical programs, as well as execute on new product opportunities. The company is developing a proprietary formulation of inhaled DHE for the potential rapid treatment of migraine and a proprietary formulation of nebulized budesonide for the potential treatment of asthma in both pediatric and adult populations.

"Our expanded Mountain View facilities provide our employees with a vibrant, open working environment," said Timothy S. Nelson, MAP Pharmaceuticals' President and Chief Executive Officer. "We continue to strengthen our core capabilities and infrastructure in order to deliver on our goal of developing high-value, differentiated therapies that provide improved efficacy and are easier to administer, enhancing patient compliance."

About MAP Pharmaceuticals

Located in Mountain View, California, MAP Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development of innovative therapies and inhalation delivery systems to treat a broad range of respiratory and systemic diseases. MAP Pharmaceuticals' lead product candidates include a proprietary formulation of inhaled DHE for the potential rapid onset treatment of migraine and a proprietary formulation of nebulized budesonide for the potential treatment of asthma in both pediatric and adult populations. Additional information about MAP Pharmaceuticals can be found at www.mappharma.com .

MAP Pharmaceuticals, Inc.

CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122, orljohnson@mappharma.com

Back to news